petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI
Alz Res Therapy. 2025-09-30; 17(1):
DOI: 10.1186/s13195-025-01839-y
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/12156
Abstract
Introduction
Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer’s disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.
Methods
We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.
Results
petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.
Discussion
petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.